An Advanced Mechanically Active Osteoarthritis‐on‐Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Cecilia Palma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via Ponzio 34/5, Milan, 20133, Italy. Hauptthemen laut MEDLINE: Diclofenac, Hyaluronic Acid, Osteoarthritis, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Cariplo.
Abstract (Originalsprache)
Current treatments for osteoarthritis (OA) often fail to address the underlying pathophysiology and may have systemic side effects, particularly associated with long‐term use of non‐steroidal anti‐inflammatory drugs (NSAIDs). Thus, researchers are currently directing their efforts toward innovative polymer‐drug combinations, such as mixtures of hyaluronic acid viscoelastic hydrogels and NSAIDs like diclofenac, to ensure sustained release of the NSAID within the joint following intra‐articular injection. However, the progress of novel injectable therapies for OA is hindered by the absence of preclinical models that accurately represent the pathology of the disease. The uBeat® MultiCompress platform is here presented as a novel approach for studying anti‐OA injectable therapeutics on human mechanically‐damaged OA cartilage microtissues, in a physiologically relevant environment. This platform can accommodate injectable therapeutic formulations and is successfully tested with SYN321, a novel diclofenac‐sodium hyaluronate conjugate under development as a treatment for knee OA. Results indicate the platform's effectiveness in evaluating therapeutic potential, showing downregulation of inflammatory markers and reduction in matrix degradation in OA cartilage micro‐tissues treated with SYN321. The uBeat® MultiCompress platform thus represents a valuable tool for OA research, offering a bridge between traditional in vitro studies and potential clinical applications, with implications for future drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via Ponzio 34/5, Milan, 20133, Italy.
- BiomimX Srl, Viale Decumano 41, MIND - Milano Innovation District, Milan, 20157, Italy.
- Recipharm OT Chemistry AB, Virdings allé 18, Uppsala, 754 50, Sweden.
- UB-consulting AB, Trädgårdsgatan 7A, Uppsala, 753 09, Sweden.
- Synartro AB, Dalgatan 16A, Uppsala, 752 18, Sweden.
ORCID-Profile: Cecilia Palma, Stefano Piazza, Roberta Visone, Antonio Bermejo Gómez, Marco Rasponi, Paola Occhetta
Förderung
- Fondazione Cariplo
Zitieren
APA
Palma, C., Piazza, S., Visone, R., Ringom, R., Björklund, U., Bermejo Gómez, A., Rasponi, M., & Occhetta, P. (2024). An Advanced Mechanically Active Osteoarthritis‐on‐Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401187
Vancouver
Palma C, Piazza S, Visone R, Ringom R, Björklund U, Bermejo Gómez A, et al. An Advanced Mechanically Active Osteoarthritis‐on‐Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401187
BibTeX
@article{Palma2024,
author = {Palma, Cecilia and Piazza, Stefano and Visone, Roberta and Ringom, Rune and Björklund, Ulf and Bermejo Gómez, Antonio and Rasponi, Marco and Occhetta, Paola},
title = {An Advanced Mechanically Active Osteoarthritis‐on‐Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401187}
}
EUVIMED